DPP-4 inhibitors and angioedema: A cause for concern?

Annals of Allergy, Asthma and Immunology

Volumn 106, Issue 5, 2011, Pages 436-438

  Byrd, Jennifer S ^a   Minor, Deborah S ^a   Elsayed, Raghda ^b   Marshall, Gailen D ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b Providence Medical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PLACEBO; RAPAMYCIN; SITAGLIPTIN; SUBSTANCE P; VILDAGLIPTIN;

ANGIONEUROTIC EDEMA; CAUSAL ATTRIBUTION; CORRELATIONAL STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RECALL; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; ENZYME ACTIVITY; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT;

EID: 79955598076     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2011.02.012     Document Type: Article

References (18)

1. Lin RY, Shah SN. Increasing hospitalizations due to angioedema in the United States. Ann Allergy Asthma Immunol. 2008;101:185-192.
2. Januvia (sitagliptin) tablets. Whitehouse Station (NJ): Merck & Co., Inc.; 2010 Sep. Package insert.
3. Onglyza (saxagliptin) tablets. Princeton (NJ): Bristol-Myers Squibb Co.; 2009 Jul. Package insert.
4. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-559.
5. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type-2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556-1568.
6. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009;54:516-523.
7. Desai S, Brinker A, Swann J, Iyasu S. Sitagliptin-associated drug allergy: review of spontaneous adverse event reports. Arch Intern Med. 2010;170:1169-1171.
8. Marney A, Kunchakarra Siri, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension. 2010;56:728-733.
9. ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmistartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559. (Pubitemid 351522739)
10. Skalli S, Wion-Barbott N, Baudrant M, Lablanche S, Benhamou PY, Halimi S. Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report. Diabet Med. 2010;27:486-487.
11. Byrd JB, Touzin K, Sile S, et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor-associated angioedema. Hypertension. 2008;51:141-147. (Pubitemid 350307116)
12. Hoover T, Lippmann M, Grouzmann E, Marceau F, Herscu P. Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors. Clin Exp Allergy. 2010;40:50-61.
13. Fryer RM, Segreti J, Banfor PN, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol. 2008;153:947-955. (Pubitemid 351328937)
14. Emanueli C, Grady EF, Madeddu P, et al. Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension. 1998;31:1299-1304. (Pubitemid 28248831)
15. Lefebvre J, Murphey LJ, Hartert TV, Shan RJ, Simmons WH, Brown NJ. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension. 2002;39:460-464. (Pubitemid 34165165)
16. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003:40:209-294. (Pubitemid 36775376)
17. Duerr M, Glander P, Diekmann F, Dragun D, Neumayer H, Budde K. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol. 2010;5:703-708.
18. Mannucci E, Pala L, Ciani S, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia. 2005;48:1168-1172. (Pubitemid 40909653)